ClinicalTrials.gg
CompletedNCT01600950Updated Oct 7, 2014Results posted

A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus

A Phase 1 interventional study of LY2963016 and Lantus in Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
58th of 66
20 · median 73
Started
2012
with 7 others
Phase 1
14 of 66
none open now
Registered
36th of 66
by date
Lead sponsor
4 of 66
Eli Lilly and Company

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 58th largest by enrollment, is one of 8 that started in 2012, is one of 14 in phase 1, and was the 36th registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

The study involves a single injection of LY2963016 and a single injection of Lantus, on 2 separate occasions in participants with type I diabetes. Following each dose, participants will undergo a glucose clamp which lasts for 42 hours each time. There will be at least 7 days between the two periods, during which time there will be no study treatment, but participants will resume their regular therapy. The duration of this study can be up to 9.5 weeks. The purposes of this study are to understand how the blood sugar lowering effect of LY2963016 compares to that of Lantus, and to determine how LY2963016 and Lantus are metabolized by participants with type I diabetes.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have type 1 diabetes mellitus (T1DM) based on the disease diagnostic criteria
  • have had a duration of diabetes ≥1 year
  • have ≤10.0%
  • have fasting C-peptide ≤0.3 nanomoles per liter (nmol/L)
  • have a ≤29 kilograms per square meter (kg/m²)
  • have venous access sufficient to allow blood sampling and cannulation for clamp procedures

Exclusion criteria

Exclusion Criteria:

  • are currently enrolled in, have completed, or discontinued within the last 30 days from, a clinical trial involving an drug or device or off-label use of a drug or device
  • have a total insulin requirement >1.2 units per kilogram per day (U/kg/day)
  • have a history of proliferative retinopathy
  • have known allergies to insulin glargine, insulin lispro, heparin, or related compounds
  • have an (ECG) reading considered outside the normal limits
  • have an abnormal blood pressure
  • have abnormal clinical laboratory tests
  • have a history or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
  • history of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in first-degree relatives
  • show evidence of significant active neuropsychiatric disease
  • regular use of known drugs of abuse and/or show positive findings on drug screening
  • show evidence of (HIV) and/or positive human HIV antibodies
  • show evidence of and/or positive hepatitis C antibody
  • show evidence of and/or positive hepatitis B surface antigen
  • are women with a positive pregnancy test or women who are lactating
  • have an average weekly alcohol intake that exceeds 21 units per week (males) or 14 units per week (females)
  • had more than 1 episode of severe hypoglycemia within 6 months prior to study
  • undergoing therapy for a other than basal cell or squamous cell skin cancer
  • had a blood transfusion or severe blood loss within 3 months; made a blood donation within 30 days prior to study entry; or have known hemoglobinopathy, haemolytic anemia, or sickle cell anemia
  • are receiving systemic therapy
  • have irregular sleep/wake cycle (for example, participants who sleep during the day and work during the night)
  • show a history of adverse reactions to heparin, including heparin-induced thrombocytopenia
  • smoke more than 10 cigarettes (or equivalent other tobacco products) per day
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    LY2963016

    A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.

    Drug: LY2963016

  • Active comparator
    Lantus

    A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.

    Drug: Lantus

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics: Duration of Action of LY2963016 and Lantus

    Duration of action is defined as the period of time elapsed between dose administration and the time at which the participant's blood glucose is consistently \>150 milligrams/deciliter (mg/dL) without any glucose infusion. Participants whose blood glucose did not rise to 150 mg/dL were censored 42 hours postdose.

    Time frame: Periods 1 and 2: Baseline up to 42 hours postdose

Secondary outcomes

  1. Maximum Glucose Infusion Rate (Rmax)

    Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain a target blood glucose level of 100 milligrams/deciliter (mg/dL) \[5.6 millimoles/Liter (mmol/L)\] and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate. Data presented are the maximum infusion rates, adjusted by body weight.

    Time frame: Periods 1 and 2: Baseline up to 42 hours postdose

  2. Total Glucose Infused (Gtot)

    Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate. Data presented are the total glucose infused, adjusted by body weight.

    Time frame: Periods 1 and 2: Baseline up to 42 hours postdose

  3. Time of Maximum Glucose Infusion Rate (tRmax)

    tRmax is the time to reach maximum glucose infusion rate and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate.

    Time frame: Periods 1 and 2: Baseline up to 42 hours postdose

  4. Pharmacokinetics: Maximum Concentration (Cmax) of LY2963016 and Lantus

    Cmax was not analyzed because of insufficient data due to concentrations being below the quantifiable lower limit of the assay.

    Time frame: Periods 1 and 2: Baseline up to 42 hours postdose

  5. Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus

    AUC was not analyzed because of insufficient data due to concentrations being below the quantifiable lower limit of the assay.

    Time frame: Periods 1 and 2: Baseline up to 42 hours postdose

07

Results

Posted Oct 7, 2014

Participant flow

Period 1
Participant flow — Period 1
MilestoneLY2963016/LantusLantus/LY2963016
Started1010
Completed1010
Not completed00
Period 2
Participant flow — Period 2
MilestoneLY2963016/LantusLantus/LY2963016
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryPharmacodynamics: Duration of Action of LY2963016 and Lantus

Duration of action is defined as the period of time elapsed between dose administration and the time at which the participant's blood glucose is consistently \>150 milligrams/deciliter (mg/dL) without any glucose infusion. Participants whose blood glucose did not rise to 150 mg/dL were censored 42 hours postdose.

Time frame:
Periods 1 and 2: Baseline up to 42 hours postdose
Reported as:
Median · hours (hr)
Pharmacodynamics: Duration of Action of LY2963016 and Lantus
hours (hr)LY2963016Lantus
Pharmacodynamics: Duration of Action of LY2963016 and Lantus37.13 (2.8 to 40.5)40.00 (2.0 to 41.5)
SecondaryMaximum Glucose Infusion Rate (Rmax)

Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain a target blood glucose level of 100 milligrams/deciliter (mg/dL) \[5.6 millimoles/Liter (mmol/L)\] and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate. Data presented are the maximum infusion rates, adjusted by body weight.

Time frame:
Periods 1 and 2: Baseline up to 42 hours postdose
Reported as:
Geometric mean · milligrams/kilogram/minute (mg/kg/min)
Maximum Glucose Infusion Rate (Rmax)
milligrams/kilogram/minute (mg/kg/min)LY2963016Lantus
Maximum Glucose Infusion Rate (Rmax)0.530 ± 2540.611 ± 310
SecondaryTotal Glucose Infused (Gtot)

Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate. Data presented are the total glucose infused, adjusted by body weight.

Time frame:
Periods 1 and 2: Baseline up to 42 hours postdose
Reported as:
Geometric mean · milligrams/kilogram (mg/kg)
Total Glucose Infused (Gtot)
milligrams/kilogram (mg/kg)LY2963016Lantus
Total Glucose Infused (Gtot)4.60 ± 10906.52 ± 1160
SecondaryTime of Maximum Glucose Infusion Rate (tRmax)

tRmax is the time to reach maximum glucose infusion rate and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate.

Time frame:
Periods 1 and 2: Baseline up to 42 hours postdose
Reported as:
Median · hours (hr)
Time of Maximum Glucose Infusion Rate (tRmax)
hours (hr)LY2963016Lantus
Time of Maximum Glucose Infusion Rate (tRmax)9.90 (1.50 to 30.1)11.7 (1.00 to 29.6)
SecondaryPharmacokinetics: Maximum Concentration (Cmax) of LY2963016 and Lantus

Cmax was not analyzed because of insufficient data due to concentrations being below the quantifiable lower limit of the assay.

Time frame:
Periods 1 and 2: Baseline up to 42 hours postdose

No measurements were reported for this outcome.

SecondaryPharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus

AUC was not analyzed because of insufficient data due to concentrations being below the quantifiable lower limit of the assay.

Time frame:
Periods 1 and 2: Baseline up to 42 hours postdose

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2963016—0/20 (0%)4/20 (20%)
Lantus—0/20 (0%)3/20 (15%)
Most frequent other events
Most frequent other events
EventLY2963016Lantus
HeadacheNervous system disorders1/202/20
Abdominal pain upperGastrointestinal disorders1/200/20
NauseaGastrointestinal disorders1/200/20
ArthralgiaMusculoskeletal and connective tissue disorders1/200/20
Back painMusculoskeletal and connective tissue disorders1/201/20
DizzinessNervous system disorders1/200/20

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)All Participants
Mean41.5 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female0
Male20
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Participants
Germany20
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neuss, 41460, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2012
First posted
May 17, 2012
Start
May 2012
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01600950
Responsible party
Sponsor
First posted
May 17, 2012
Start date
May 2012
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion